Pharvaris to Present Deucrictibant Clinical Data at Upcoming Congresses
2024-03-06
临床2期临床3期临床结果
Pharvaris to Present Deucrictibant Clinical Data at Upcoming Congresses
ZUG, Switzerland, March 06, 2024 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin B2 receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks, today announced the acceptance of abstracts for presentation at two upcoming congresses: the 3rd National Congress of the Italian Network for Hereditary and Acquired Angioedema (ITACA), to be held from March 14-16, 2024, in Milan, Italy, and the 2024 HAE International (HAEi) Regional Conference Americas, to be held from March 15-17, 2024, in Panama City, Panama. Details of the presentations are as follows:
3rd ITACA National Congress, Milan, Italy, March 14-16, 2024.
Title: Design of RAPIDe-3 Phase 3 Trial: Efficacy and Safety of the Oral Bradykinin B2 Receptor Antagonist Deucrictibant Immediate-Release Capsule in Treatment of Hereditary Angioedema Attacks
Presenter: Mauro Cancian, M.D., Ph.D.
Format: Poster Presentation
Date, time: Friday, March 15, 4:30 p.m. CET (11:30 a.m. EDT)
Title: Efficacy and Safety of Bradykinin B2 Receptor Antagonism with Deucrictibant Immediate-Release Capsule for Treatment of Hereditary Angioedema Attacks: Results of RAPIDe-1 Phase 2 Trial
Presenter: Giuseppe Spadaro, M.D., Ph.D.
Format: Poster Presentation
Date, time: Friday, March 15, 4:30 p.m. CET (11:30 a.m. EDT)
Title: Prophylactic Treatment with Oral Deucrictibant Improves Health-Related Quality of Life of Patients with Hereditary Angioedema
Presenter: Andrea Zanichelli, M.D., Ph.D.
Format: Poster Presentation
Date, time: Friday, March 15, 4:30 p.m. CET (11:30 a.m. EDT)
Title: Need for Caregiver Support for People Living With Hereditary Angioedema in European Countries
Presenter: Andrea Zanichelli, M.D., Ph.D.
Format: Poster Presentation
Date, time: Friday, March 15, 4:30 p.m. CET (11:30 a.m. EDT)
Title: Efficacy and Safety of Oral Deucrictibant, a Bradykinin B2 Receptor AntagonistBradykinin B2 Receptor Antagonist, in Prophylaxis of Hereditary Angioedema Attacks: Results of CHAPTER-1 Phase 2 Trial
Presenter: Mauro Cancian, M.D., Ph.D.
Format: Selected Oral and Poster Presentation
Date, time: Saturday, March 16, 10:00 a.m. CET (5:00 a.m. EDT)
2024 HAEi Regional Conference Americas, Panama City, Panama, March 15-17, 2024.
Title: Efficacy and Safety of the Oral Bradykinin B2 Receptor Antagonist Deucrictibant Immediate-Release Capsule in Treatment of Hereditary Angioedema Attacks: RAPIDe-3 Phase 3 Trial Design
Presenter: Anete Grumach, M.D., Ph.D.
Format: Poster Presentation
Date, time: Friday, March 15, 7:20 p.m. EDT
Title: Efficacy and Safety of Bradykinin B2 Receptor Antagonism with Deucrictibant Immediate-Release Capsule for Treatment of Hereditary Angioedema Attacks: Results of RAPIDe-1 Phase 2 Trial
Presenter: Markus Magerl, M.D.
Format: Poster Presentation
Date, time: Friday, March 15, 7:20 p.m. EDT
Title: Early-Onset Response to the Oral Bradykinin B2 Receptor Antagonist Deucrictibant Immediate-Release Capsule in Patients with Hereditary Angioedema Attacks
Presenter: Marcus Maurer, M.D.
Format: Poster Presentation
Date, time: Friday, March 15, 7:20 p.m. EDT
Title: Efficacy and Safety of Oral Deucrictibant, a Potent Bradykinin B2 Receptor AntagonistBradykinin B2 Receptor Antagonist, in Prophylaxis of Hereditary Angioedema Attacks: Results of CHAPTER-1 Phase 2 Trial
Presenter: Marc A. Riedl, M.D., M.S.
Format: Oral Presentation
Date, time: Saturday, March 16, 9:30 a.m. EDT
Title: Understanding Patient Reasons not to Treat All Hereditary Angioedema (HAE) Attacks and Characteristics of Untreated HAE Attacks: Results from a Real World Survey
Presenter: William Lumry, M.D.
Format: Oral Presentation
Date, time: Saturday, March 16, 11:15 a.m. EDT
The posters and presentation slides will be made available on the Investors section of the Pharvaris website at the beginning of the respective presentations at: https://ir.pharvaris.com/news-events/events-presentations.
About Pharvaris
Building on its deep-seated roots in HAE, Pharvaris is a clinical-stage company developing novel, oral bradykinin B2 receptor antagonists to treat and prevent HAE attacks. By directly pursuing this clinically proven therapeutic target with novel small molecules, the Pharvaris team aspires to offer people with all sub-types of HAEHAE efficacious, safe, and easy-to-administer alternatives to treat attacks, both on-demand and prophylactically. The company brings together the best talent in the industry with deep expertise in rare diseases and HAE. For more information, visit https://pharvaris.com/.
Contact
Maggie Beller
Executive Director, Head of External and Internal Communications
maggie.beller@pharvaris.com
更多内容，请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。
适应症
热门报告
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。